Regulatory innovation in postmarketing risk assessment and management

J. A. Staffa, G. J. Dal Pan

Research output: Contribution to journalArticle

Abstract

The contemporary science of drug safety seeks not only to identify the risks associated with the use of medicines but also to quantify these risks, identify their risk factors, and assess strategies to minimize them. It monitors the use of medicines in actual practice to understand how the medical care system interacts with the intrinsic pharmacologic properties of medicines to produce the observed effects. To the extent possible, these analyses use a population-based approach that at times requires creativity and innovation. The key to effective safety management of drugs in the postmarketing setting is the ability to access sufficient good-quality data, interpret the data appropriately, challenge old assumptions, and define best practices in contemporary drug safety approaches.

Original languageEnglish (US)
Pages (from-to)555-557
Number of pages3
JournalClinical Pharmacology and Therapeutics
Volume91
Issue number3
DOIs
StatePublished - Mar 2012
Externally publishedYes

Fingerprint

Risk Management
Pharmaceutical Preparations
Safety
Safety Management
Aptitude
Creativity
Practice Guidelines
Population

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Regulatory innovation in postmarketing risk assessment and management. / Staffa, J. A.; Dal Pan, G. J.

In: Clinical Pharmacology and Therapeutics, Vol. 91, No. 3, 03.2012, p. 555-557.

Research output: Contribution to journalArticle

Staffa, J. A. ; Dal Pan, G. J. / Regulatory innovation in postmarketing risk assessment and management. In: Clinical Pharmacology and Therapeutics. 2012 ; Vol. 91, No. 3. pp. 555-557.
@article{4cac178d25f7420e8ec62474c8a56237,
title = "Regulatory innovation in postmarketing risk assessment and management",
abstract = "The contemporary science of drug safety seeks not only to identify the risks associated with the use of medicines but also to quantify these risks, identify their risk factors, and assess strategies to minimize them. It monitors the use of medicines in actual practice to understand how the medical care system interacts with the intrinsic pharmacologic properties of medicines to produce the observed effects. To the extent possible, these analyses use a population-based approach that at times requires creativity and innovation. The key to effective safety management of drugs in the postmarketing setting is the ability to access sufficient good-quality data, interpret the data appropriately, challenge old assumptions, and define best practices in contemporary drug safety approaches.",
author = "Staffa, {J. A.} and {Dal Pan}, {G. J.}",
year = "2012",
month = "3",
doi = "10.1038/clpt.2011.289",
language = "English (US)",
volume = "91",
pages = "555--557",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Regulatory innovation in postmarketing risk assessment and management

AU - Staffa, J. A.

AU - Dal Pan, G. J.

PY - 2012/3

Y1 - 2012/3

N2 - The contemporary science of drug safety seeks not only to identify the risks associated with the use of medicines but also to quantify these risks, identify their risk factors, and assess strategies to minimize them. It monitors the use of medicines in actual practice to understand how the medical care system interacts with the intrinsic pharmacologic properties of medicines to produce the observed effects. To the extent possible, these analyses use a population-based approach that at times requires creativity and innovation. The key to effective safety management of drugs in the postmarketing setting is the ability to access sufficient good-quality data, interpret the data appropriately, challenge old assumptions, and define best practices in contemporary drug safety approaches.

AB - The contemporary science of drug safety seeks not only to identify the risks associated with the use of medicines but also to quantify these risks, identify their risk factors, and assess strategies to minimize them. It monitors the use of medicines in actual practice to understand how the medical care system interacts with the intrinsic pharmacologic properties of medicines to produce the observed effects. To the extent possible, these analyses use a population-based approach that at times requires creativity and innovation. The key to effective safety management of drugs in the postmarketing setting is the ability to access sufficient good-quality data, interpret the data appropriately, challenge old assumptions, and define best practices in contemporary drug safety approaches.

UR - http://www.scopus.com/inward/record.url?scp=84857236220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857236220&partnerID=8YFLogxK

U2 - 10.1038/clpt.2011.289

DO - 10.1038/clpt.2011.289

M3 - Article

C2 - 22297386

AN - SCOPUS:84857236220

VL - 91

SP - 555

EP - 557

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -